Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Most common gastrointestinal issues seen were nausea/vomiting, abdominal pain, and diarrhea. HealthDay News — The rate of emergency department visits for adverse events among patients dispensed ...

semaglutide caused thyroid tumors or thyroid cancer. Semaglutide cannot be used by pregnant ladies and lactating mothers. It can be used by adults more than 18 years of age. Keep out of the reach ...

Five scientists who helped develop the blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Wegovy) are among recipients of the 2025 $3 million Breakthrough Prizes. (Nature) Lawyers for ...